home / stock / mrna / mrna quote
Last: | $46.83 |
---|---|
Change Percent: | -0.28% |
Open: | $50.42 |
Close: | $46.83 |
High: | $50.9 |
Low: | $46.57 |
Volume: | 13,518,572 |
Last Trade Date Time: | 11/08/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$46.83 | $50.42 | $46.83 | $50.9 | $46.57 | 13,518,572 | 11-08-2024 |
$50.28 | $56.6 | $50.28 | $56.695 | $49.94 | 18,211,730 | 11-07-2024 |
$51.81 | $52.61 | $51.81 | $52.855 | $49.6 | 10,681,548 | 11-06-2024 |
$53.29 | $53.53 | $53.29 | $54.32 | $52.08 | 5,765,855 | 11-05-2024 |
$53.54 | $54.6 | $53.54 | $55.6499 | $53.41 | 4,037,232 | 11-04-2024 |
$54.63 | $54.49 | $54.63 | $55.35 | $53.89 | 4,787,050 | 11-01-2024 |
$54.36 | $54.35 | $54.36 | $54.575 | $52.92 | 4,511,436 | 10-31-2024 |
$54.72 | $54.37 | $54.72 | $55.035 | $53.5 | 4,280,556 | 10-30-2024 |
$55.22 | $55.21 | $55.22 | $57.69 | $54.88 | 5,592,539 | 10-29-2024 |
$54.8 | $53.31 | $54.8 | $55.77 | $53.1 | 5,011,899 | 10-28-2024 |
$53.09 | $53.01 | $53.09 | $54.51 | $52.8 | 3,704,422 | 10-25-2024 |
$52.8 | $53.39 | $52.8 | $53.836 | $52.26 | 3,767,076 | 10-24-2024 |
$53.39 | $53.22 | $53.39 | $54.74 | $52.77 | 4,288,942 | 10-23-2024 |
$53.4 | $53.67 | $53.4 | $54.7893 | $52.81 | 3,559,675 | 10-22-2024 |
$53.8 | $53.82 | $53.8 | $54.76 | $53.05 | 4,092,122 | 10-21-2024 |
$54.1 | $54.535 | $54.1 | $55.1 | $53.55 | 6,754,694 | 10-18-2024 |
$54.82 | $57.08 | $54.82 | $57.145 | $54.82 | 5,423,743 | 10-17-2024 |
$57.46 | $57.82 | $57.46 | $58.45 | $57.12 | 3,258,207 | 10-16-2024 |
$57.31 | $57.64 | $57.31 | $58.62 | $57.1201 | 4,087,301 | 10-15-2024 |
$57.73 | $57.9 | $57.73 | $58.96 | $57.05 | 3,361,308 | 10-14-2024 |
News, Short Squeeze, Breakout and More Instantly...
2024-11-08 10:00:00 ET Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although drugs and vaccines benefit from patent protection for some time, this will eventually run out, at which point the inv...
mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and Qatar CAMBRIDGE, MA / ACCESSWIRE / November 8,...
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma PR Newswire New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADE...